Voyager Therapeutics
VYGR
119 hedge funds and large institutions have $547M invested in Voyager Therapeutics in 2018 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 40 increasing their positions, 35 reducing their positions, and 23 closing their positions.
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
23% more call options, than puts
Call options by funds: $655K | Put options by funds: $533K
14% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 35
0.91% less ownership
Funds ownership: 90.04% → 89.13% (-0.91%)
4% less capital invested
Capital invested by funds: $569M → $547M (-$21.6M)
5% less funds holding
Funds holding: 125 → 119 (-6)
26% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 23
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$24.8M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$12.9M |
| 3 |
BB
BB Biotech
Schaffhausen,
Switzerland
|
+$5.56M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$4.02M |
| 5 |
HCM
Highline Capital Management
New York
|
+$3.09M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TGI
TRV GP III
Boston,
Massachusetts
|
-$28.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$18.3M |
| 3 |
LCM
Laurion Capital Management
New York
|
-$6.96M |
| 4 |
Millennium Management
New York
|
-$2.92M |
| 5 |
PP
PDT Partners
New York
|
-$2.1M |
VYGR Hedge Fund Activity: Q3 2018 in Review
119 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Voyager Therapeutics (VYGR) for Q3 2018, worth a combined $547M — down 3.8% from $569M a quarter earlier.
Sellers outnumbered buyers: 23 funds closed out of VYGR and 17 opened new positions — a net loss of 6 holders — while 35 trimmed existing stakes and 40 added.
The largest buyer was Armistice Capital, adding an estimated $24.8M. The largest seller was TRV GP III, cutting an estimated $28.8M.
- 119 institutional investors held Voyager Therapeutics (VYGR) as of Q3 2018, down from 125 in Q2 2018.
- Funds reported $547M of Voyager Therapeutics stock for Q3 2018, down 3.8% quarter-over-quarter.
- 17 funds opened new Voyager Therapeutics positions in Q3 2018 and 23 closed out, a net change of -6 holders.
- The largest Voyager Therapeutics buyer in Q3 2018 was Armistice Capital, an estimated $24.8M added.
- The largest Voyager Therapeutics seller in Q3 2018 was TRV GP III, an estimated $28.8M sold.
Based on aggregated 13F filings for Q3 2018.